Aaltonen et al., based on Kaplan-Meier survival analysis in a systematic review regarding the anti-TNFα, showed that the probability of discontinuing the treatment within 6, 12, 24, and 36 months was 16%, 27%, 37%, and 43%, respectively in patients with RA. Here, TNF is linked to rheumatoid arthritis.